Influvac (Influenza Virus B/Austria/1359417/2021-Like Strain (B/Austria/1359417/2021, Bvr-26), Influenza A/Vic)

The vaccine contains split‑virion antigens from the selected influenza strains. After injection, these antigens are processed by antigen‑presenting cells, which stimulate the adaptive immune system to produce strain‑specific antibodies against hemagglutinin and neuraminidase. This antibody response provides active immunity that can neutralize the targeted viruses if exposure occurs.

The prescribed dose of Influvac is determined by the treating healthcare professional. Typically, a single intramuscular injection of the vaccine is given each influenza season, but the exact volume and administration schedule are set by the prescriber based on local guidelines and patient characteristics.

Safety data for Influvac in pregnancy and lactation are limited. The vaccine may be administered when the potential benefit to the mother outweighs any uncertain risk to the fetus. Healthcare providers should evaluate individual circumstances and discuss the decision with the patient. Breastfeeding is not a contraindication, but professional advice is recommended.

To place an order, submit an enquiry on the Influvac product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the enquiry, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain handling) and any necessary import documentation.

Influvac is a split‑virion, inactivated vaccine that includes specific B and A strains. Compared with live‑attenuated or recombinant influenza vaccines, Influvac does not contain live virus and is suitable for a broader range of recipients, including those with certain immunocompromising conditions. Efficacy and safety profiles are comparable to other licensed inactivated influenza vaccines that target the same strains.

Influvac must be stored in a refrigerated environment at 2 °C to 8 °C. The vials should be kept in their original packaging to protect from light, should not be frozen, and must not be shaken vigorously. Maintaining the cold chain during transport and storage is essential to preserve vaccine potency.

Influvac is administered by a single intramuscular injection, usually into the deltoid muscle of the upper arm for adults or the anterolateral thigh for young children. The injection is performed by a qualified healthcare professional using aseptic technique. The dose is typically given once per influenza season.

The most serious adverse events reported with Influvac are severe allergic reactions, including anaphylaxis, and rare occurrences of Guillain‑Barré syndrome. These events require immediate medical attention. Patients should be observed for a short period after vaccination, and any signs of severe reaction should be reported to a healthcare provider promptly.

Influvac should not be given to individuals with a known severe allergy to any component of the vaccine or to those who have experienced a severe allergic reaction (e.g., anaphylaxis) after a previous dose of any influenza vaccine. Persons with a history of Guillain‑Barré syndrome following a prior influenza vaccination should also avoid this vaccine unless advised otherwise by a physician.